These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 27671498)
21. Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors. Jeankumar VU; Reshma RS; Vats R; Janupally R; Saxena S; Yogeeswari P; Sriram D Eur J Med Chem; 2016 Oct; 122():216-231. PubMed ID: 27371925 [TBL] [Abstract][Full Text] [Related]
22. A short-term model for preliminary screening of potential anti-tubercular compounds. Jhamb SS; Singh PP Scand J Infect Dis; 2009; 41(11-12):886-9. PubMed ID: 19922075 [TBL] [Abstract][Full Text] [Related]
23. Development of antitubercular compounds based on a 4-quinolylhydrazone scaffold. Further structure-activity relationship studies. Gemma S; Savini L; Altarelli M; Tripaldi P; Chiasserini L; Coccone SS; Kumar V; Camodeca C; Campiani G; Novellino E; Clarizio S; Delogu G; Butini S Bioorg Med Chem; 2009 Aug; 17(16):6063-72. PubMed ID: 19620006 [TBL] [Abstract][Full Text] [Related]
24. Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis. Lelovic N; Mitachi K; Yang J; Lemieux MR; Ji Y; Kurosu M J Antibiot (Tokyo); 2020 Nov; 73(11):780-789. PubMed ID: 32472054 [TBL] [Abstract][Full Text] [Related]
25. Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies. Wilson CR; Gessner RK; Moosa A; Seldon R; Warner DF; Mizrahi V; Soares de Melo C; Simelane SB; Nchinda A; Abay E; Taylor D; Njoroge M; Brunschwig C; Lawrence N; Boshoff HIM; Barry CE; Sirgel FA; van Helden P; Harris CJ; Gordon R; Ghidelli-Disse S; Pflaumer H; Boesche M; Drewes G; Sanz O; Santos G; Rebollo-Lopez MJ; Urones B; Selenski C; Lafuente-Monasterio MJ; Axtman M; Lelièvre J; Ballell L; Mueller R; Street LJ; Ghorpade SR; Chibale K J Med Chem; 2017 Dec; 60(24):10118-10134. PubMed ID: 29148755 [TBL] [Abstract][Full Text] [Related]
26. Synthesis and structure-activity relationships of phenyl-substituted coumarins with anti-tubercular activity that target FadD32. Kawate T; Iwase N; Shimizu M; Stanley SA; Wellington S; Kazyanskaya E; Hung DT Bioorg Med Chem Lett; 2013 Nov; 23(22):6052-9. PubMed ID: 24103299 [TBL] [Abstract][Full Text] [Related]
27. Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents. Ng PS; Manjunatha UH; Rao SP; Camacho LR; Ma NL; Herve M; Noble CG; Goh A; Peukert S; Diagana TT; Smith PW; Kondreddi RR Eur J Med Chem; 2015 Dec; 106():144-56. PubMed ID: 26544629 [TBL] [Abstract][Full Text] [Related]
28. Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis. Hameed P S; Patil V; Solapure S; Sharma U; Madhavapeddi P; Raichurkar A; Chinnapattu M; Manjrekar P; Shanbhag G; Puttur J; Shinde V; Menasinakai S; Rudrapatana S; Achar V; Awasthy D; Nandishaiah R; Humnabadkar V; Ghosh A; Narayan C; Ramya VK; Kaur P; Sharma S; Werngren J; Hoffner S; Panduga V; Kumar CN; Reddy J; Kumar K N M; Ganguly S; Bharath S; Bheemarao U; Mukherjee K; Arora U; Gaonkar S; Coulson M; Waterson D; Sambandamurthy VK; de Sousa SM J Med Chem; 2014 Jun; 57(11):4889-905. PubMed ID: 24809953 [TBL] [Abstract][Full Text] [Related]
29. Identification of inhibitors against Mycobacterium tuberculosis thiamin phosphate synthase, an important target for the development of anti-TB drugs. Khare G; Kar R; Tyagi AK PLoS One; 2011; 6(7):e22441. PubMed ID: 21818324 [TBL] [Abstract][Full Text] [Related]
35. Aminopyrazolo[1,5-a]pyrimidines as potential inhibitors of Mycobacterium tuberculosis: Structure activity relationships and ADME characterization. Soares de Melo C; Feng TS; van der Westhuyzen R; Gessner RK; Street LJ; Morgans GL; Warner DF; Moosa A; Naran K; Lawrence N; Boshoff HI; Barry CE; Harris CJ; Gordon R; Chibale K Bioorg Med Chem; 2015 Nov; 23(22):7240-50. PubMed ID: 26522089 [TBL] [Abstract][Full Text] [Related]
36. Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656). Li X; Hernandez V; Rock FL; Choi W; Mak YSL; Mohan M; Mao W; Zhou Y; Easom EE; Plattner JJ; Zou W; Pérez-Herrán E; Giordano I; Mendoza-Losana A; Alemparte C; Rullas J; Angulo-Barturen I; Crouch S; Ortega F; Barros D; Alley MRK J Med Chem; 2017 Oct; 60(19):8011-8026. PubMed ID: 28953378 [TBL] [Abstract][Full Text] [Related]
37. Anti-tubercular agents. Part 3. Benzothiadiazine as a novel scaffold for anti-Mycobacterium activity. Kamal A; Reddy KS; Ahmed SK; Khan MN; Sinha RK; Yadav JS; Arora SK Bioorg Med Chem; 2006 Feb; 14(3):650-8. PubMed ID: 16203154 [TBL] [Abstract][Full Text] [Related]
38. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis? Goldman RC Tuberculosis (Edinb); 2013 Nov; 93(6):569-88. PubMed ID: 24119636 [TBL] [Abstract][Full Text] [Related]